Pharmaceuticals Global News & Press Release Distribution

Pharmaceuticals

All
APAC

Fangzhou Inc. Announces Inclusion of Its Shares in Hang Seng Hong Kong-Listed Biotech Index

HONG KONG, Dec. 3, 2024 /PRNewswire/ -- Fangzhou Inc. ("Fangzhou" or the "Company") (06086.HK), a leader in Internet healthcare solutions, announced today that the Company's Ordinary Shares, which trade on The Stock Exchange of Hong Kong Limited ("HKEX"), will be included in the Hang Seng Hong Ko...

2024-12-03 18:47 1122

MGI Tech announces partnership with Universidad de San Martín de Porres to strengthen human genetics research

* The implementation of MGI Tech's next-generation genomic sequencing (NGS) technologies will strengthen scientific research in the country, enabling the identification of key genetic variations, contributing to disease prevention, and personalizing medical treatments. * A team of specialists...

2024-12-02 11:16 1073

MGI Tech announces partnership with Universidad de San Martín de Porres to strengthen human genetics research

BGM Group Ltd Pioneers Innovation in AI Technology, Fostering Holistic Integration of Healthcare and Insurtech

CHENGDU, China, Nov. 29, 2024 /PRNewswire/ -- BGM Group Ltd. (NASDAQ: BGM) ("the Company" or "BGM"), a leading global pharmaceutical enterprise, today announced its acquisition of the intelligent platform of AIX Inc. (NASDAQ: AIFU) ("AIX") valued at1 billion RMB (approximately $140 million). The ...

2024-11-29 23:58 4675

MicuRx: Successfully Completes Phase III Clinical Trial of MRX-4 for Injection in China

SHANGHAI, Nov. 29, 2024 /PRNewswire/ -- Recently, Shanghai MicuRx Pharmaceutical Co., Ltd. ("MicuRx", 688373.SH) announced the successful completion of its Phase III clinical trial of MRX-4 for injection transitioning to oral Contezolid tablets for the treatment of adult patients with complex sk...

2024-11-29 22:00 2482

Minghui Pharmaceutical Announces Positive Topline Results from Phase Ⅲ Trial of MH004 (Tofacitinib Etocomil) Ointment in Mild to Moderate Atopic Dermatitis

SHANGHAI, Nov. 29, 2024 /PRNewswire/ -- Minghui Pharmaceutical, a late-stage biopharmaceutical company dedicated to developing transformative medicines in immunology and oncology, today announced positive topline results from its phase Ⅲ trial of MH004 (tofacitinib etocomil) ointment 1.0%, a twic...

2024-11-29 20:31 2666

Akeso to Present at Citi 2024 Global Healthcare Conference and the 7th Annual Evercore HealthCONx Conference

HONG KONG, Nov. 28, 2024 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce its participation in the upcoming 7th Annual Evercore HealthCONx Conference and Citi 2024 Global Healthcare Conference, both taking place inMiami. Akeso will participate in a firesid...

2024-11-29 10:23 1251

Akeso Announced the Inclusion in China's National Reimbursement Drug List of Cadonilimab and Ivonescimab

HONG KONG, Nov. 27, 2024 /PRNewswire/ -- Akeso, Inc. (9926. HK) ("Akeso" or the "Company") is pleased to announce that two of its independently developed, globally pioneering bispecific antibody drugs—cadonilimab Injection (PD-1/CTLA-4 bispecific antibody) and ivonescimab Injection (PD-1/VEGF bi...

2024-11-28 11:58 1738

111, Inc. Announces Third Quarter 2024 Unaudited Financial Results

* Maintained Operational Profitability for the Third Consecutive Quarter * Operating Expenses as a Percentage of Revenues Decreased 160 Basis Points YoY * Held Positive Operating Cash Flow for Three Consecutive Quarters SHANGHAI, Nov. 27, 2024 /PRNewswire/ -- 111, Inc. ("111" or the "Company...

2024-11-27 14:00 1524

VectorBuilder and Sartorius Sign Strategic Cooperation Agreement to Advance Biopharmaceutical Innovation

GUANGZHOU, China, Nov. 26, 2024 /PRNewswire/ -- VectorBuilder, a global leader in end-to-end gene delivery services, and Sartorius, a leading international partner in life science research and the biopharmaceutical industry, recently announced a strategic cooperation agreement. The collaboration ...

2024-11-26 22:00 1805

VectorBuilder and Sartorius Sign Strategic Cooperation Agreement to Advance Biopharmaceutical Innovation

GC Biopharma and Novel Pharma First Patient Dosed in Global Phase I Clinical Trial for MPS IIIA Treatment

YONGIN, South Korea, Nov. 25, 2024 /PRNewswire/ -- GC Biopharma and Novel Pharma today announced that the first patient in the US has been dosed in multinational clinical trial with 'GC1130A', an innovative new drug for Sanfillippo syndrome type A (MPS IIIA). GC Biopharma and Novel Pharma have...

2024-11-26 08:44 1232

Duality Biologics Announces Expansion of Adcendo ApS Collaboration Through Option Exercise of Strategic License Agreement

Adcendo ApS exercises its option to utilize Duality Biologics' platform to further enhance its first-in-class ADC pipeline PRINCETON, N.J., SHANGHAI and SUZHOU, China, Nov. 25, 2024 /PRNewswire/ -- Duality Biologics ("Duality"), a clinical-stage biotech company focusing on the discovery and deve...

2024-11-26 08:30 1104

ReviR Therapeutics and Kennedy's Disease Association Partner to Advance Treatment for Rare Neuromuscular Disorder

BRISBANE, Calif., Nov. 25, 2024 /PRNewswire/ -- ReviR Therapeutics, a pioneering biotechnology company focused on developing novel small molecule RNA modulators for neurogenetic diseases, announced a groundbreaking research grant from the Kennedy's Disease Association (KDA) to advance a therapy f...

2024-11-26 01:00 1184

Cistto Launches the "Humanized Anti-Aging Global Scientist Alliance" in China, Empowering Products with Cutting-Edge Science

LOS ANGELES, Nov. 25, 2024 /PRNewswire/ -- As an emerging brand specializing in sensitive skin repair, Cistto is grounded in skin science and committed to advancing skin health through the latest dermatological breakthroughs and cutting-edge biotechnology. Cistto is steadfast in its promise to de...

2024-11-25 23:00 1522

Food Allergy: LongBio's LP-003 achieves its fourth IND approval

SHANGHAI, Nov. 25, 2024 /PRNewswire/ -- LongBio is proud to announce that the National Medical Products Administration (NMPA,China) has approved the Investigational New Drug (IND) application for LP-003, the company's next-generation anti-IgE antibody, to begin a clinical trial for the treatment ...

2024-11-25 22:00 1242

Lakeside Strengthens Market Position in China's Pharmaceutical Logistics with Key Sinopharm(Hubei) Contracts

ITASCA, Ill., Nov. 25, 2024 /PRNewswire/ -- Lakeside Holding Limited ("Lakeside" or the "Company") (Nasdaq: LSH), a U.S.-based integrated cross-border supply chain solution provider with a strategic focus on the Asian market operating under the brand American Bear Logistics ("ABL"), announces th...

2024-11-25 21:30 1427

HanAll Biopharma, Daewoong Pharmaceutical and NurrOn Pharmaceuticals Announce Successful Completion of a First-in-Human Study for Potential Disease-Modifying Therapy for Parkinson's Disease

* HL192 (ATH-399A) was well tolerated with no major safety issues in any of the 76 participants. * No serious treatment related adverse events were reported and such findings were proportional between placebo and dosed groups. * PK results support once a day dosing. ROCKVILLE, Md. and SEOUL,...

2024-11-25 20:00 1020

Hanmi Pharmaceutical and Beijing Hanmi Progress Clinical Trials of Co-developed BH3120 as a Next-Generation Cancer Immunotherapy

Hanmi unveils tiral in progress poster on BH3120 at the Society for Immunotherapy of Cancer (SITC) in the U.S. Phase 1 trial is progressing smoothly, with no dose-limiting toxicity observed Phase 1 trial evaluating the combination of BH3120 and MSD's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) un...

2024-11-25 09:30 1396

Hankyung.com introduces: MecKare, Leading the AI-powered Innovation in Health Monitoring Solution

- Leading efficient care management for the elderly with unimpeded smartcare https://img.hankyung.com/pdsdata/pr.hankyung.com/uploads/2024/11/image01-1.png SEOUL, South Korea, Nov. 23, 2024 /PRNewswire/ -- JCF Techn...

2024-11-23 21:00 2934

BGM Group Welcomes Guilin Pharma for On-site Audit and Partnership Development

CHENGDU, China, Nov. 22, 2024 /PRNewswire/ -- On November 19, Qilianshan Pharmaceutical Co., Ltd. (Qilian Pharma), a subsidiary of BGM Group Ltd, welcomed a team of experts from Guilin Pharmaceutical Co., Ltd. (Guilin Pharma), including Quality Assurance Engineer Ms. Shen and Technical Manager M...

2024-11-22 21:30 2076

Akeso's Penpulimab Combination Therapy for First-line Treatment of Hepatocellular Carcinoma Accepted by NMPA

HONG KONG, Nov. 22, 2024 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the National Medical Products Administration (NMPA) of China has accepted its supplemental new drug application (sNDA) for penpulimab, a differentiated PD-1 monoclonal antibody, in combination...

2024-11-22 19:34 1306

1 234 5 6 ... 129

Week's Top Stories

Most Reposted

PARKROYAL COLLECTION MARINA BAY IS THE FIRST HOTEL IN SINGAPORE TO ATTAIN THREE PRESTIGIOUS SUSTAINABILITY CERTIFICATIONS

[Picked up by 323 media titles]

2024-12-19 13:41